Palvella Therapeutics, Inc (PVLA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Palvella Therapeutics, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Palvella Therapeutics, Inc (PVLA) has returned 19.09% so far this year and 345.34% over the past 12 months.

Based on dividend-adjusted daily data since Dec 16, 2024, PVLA's average daily return is +0.85%, while the average monthly return is +18.79%. At this rate, your investment would double in approximately 0.3 years.

Historically, 63% of months were positive and 38% were negative. The best month was Feb 2026 with a return of +76.1%, while the worst month was Jan 2026 at -26.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 3 months.

On a daily basis, PVLA closed higher 53% of trading days. The best single day was Feb 24, 2026 with a return of +37.1%, while the worst single day was Apr 7, 2025 at -16.3%.

Palvella Therapeutics, Inc has an annualized alpha of 678.78%, beta of 1.05, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since December 17, 2024.

• This stock captured 1033.46% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -1995.85%) — a profile typical of hedging or uncorrelated assets.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PVLA ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Palvella Therapeutics, Inc (PVLA) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Palvella Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Palvella Therapeutics, Inc was 31.48%, occurring on Apr 10, 2025. Recovery took 66 trading sessions.

The current Palvella Therapeutics, Inc drawdown is 15.97%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Palvella Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Palvella Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.